Unlocking the potential of established products: toward new incentives rewarding innovation in Europe

References

• Scannell JW, Blanckley A, Boldon H, et al. Diagnosing the decline in pharmaceutical R&D efficiency. Nat Rev Drug Discov. 2012;11(3):1–15.
   Web of Science ®Google Scholar
• Pammolli F, Magazzini L, Riccaboni M. The productivity crisis in pharmaceutical R&D. Nature Rev Drug Discov. 2011;10(6):428–438.
   Web of Science ®Google Scholar
• ANSM. Temporary Recommendation for Use (RTUs) - Principles and information on the methods used by the ANSM for establishment and implementation. Saint-Denis: ANSM; 2012.
   Google Scholar
• Radley DC, Finkelstein SN, Stafford RS. Off-label prescribing among office-based physicians. Arch Intern Med. 2006;166(9):1021–1026.
   PubMed Web of Science ®Google Scholar
• Dresser R, Frader J. Off‐Label Prescribing: A Call for Heightened Professional and Government Oversight. J Law, Med Ethics. 2009;37(3):476–486.
   PubMed Web of Science ®Google Scholar
• IMS Health. IMS pharmaceutical pricing & reimbursement concise guide. France: IMS Health Incorporated; 2014.
   Google Scholar
• Navarria A, Drago V, Gozzo L, et al. Do the current performance-based schemes in Italy really work? “Success fee”: a novel measure for cost-containment of drug expenditure. Value Health. 2015;18(1):131–136.
   PubMed Web of Science ®Google Scholar
• Jommi C, Minghetti P. Pharmaceutical Pricing Policies in Italy. Pharmaceutical Prices in the 21st Century. Switzerland: Springer International Publishing; 2015. p. 131–151.
   Google Scholar
• Ghislandi S, Armeni P, Jommi C. The impact of generic reference pricing in Italy, a decade on. Eur J Health Econ. 2013;14(6):959–969.
   Web of Science ®Google Scholar
• IMS Health. IMS pharmaceutical pricing & reimbursement concise guide. Italy: IMS Health Incorporated; 2014.
   Google Scholar
• The Medicines Utilisation Monitoring Centre. National Report on Medicines use in Italy. Year 2014. Rome: AIFA; 2015.
   Google Scholar
• Determina AIFA 1267/2015. Gazetta Ufficiale della Republica Italiana Serie Generale n. 234. 2015.
   Google Scholar
• Ley 29/2006, de 26 de julio, de garantías y uso racional de los medicamentos y productos sanitarios. Boletin Oficial del Estado n. 178. 2006 Jul 27. BOE-A-2006-13554.
   Google Scholar
• Real Decreto-ley 8/2010, de 20 de mayo, por el que se adoptan medidas extraordinarias para la reducción del déficit público. Boletin Oficial Del Estado  n. 126. 2010  May 24. BOE-A-2010-8228.
   Google Scholar
• Real Decreto-ley 9/2011, de 19 de agosto, de medidas para la mejora de la calidad y cohesión del sistema nacional de salud, de contribución a la consolidación fiscal, y de elevación del importe máximo de los avales del Estado para 2011. Boletin Oficial Del Estado  n. 200. 2011 Aug 20. BOE-A-2011-14021.
   Google Scholar
• Ley 16/2003 de 28 de mayo. de cohesión y calidad del Sistema Nacional de Salud. Boletin Oficial del Estado n. 128. 2003 May 29. BOE-A-2003-10715.
   Google Scholar
• IMS Health. IMS pharmaceutical pricing & reimbursement concise guide. Spain: IMS Health Incorporated; 2014.
   Google Scholar
• IMS Health. IMS pharmaceutical pricing & reimbursement concise guide. Germany: IMS Health Incorporated; 2014.
   Google Scholar
• IMS Health. IMS pharmaceutical pricing & reimbursement concise guide. United Kingdom: IMS Health Incorporated; 2014.
   Google Scholar
• EMA. Risk-management plans. [cited 2015 Nov 17]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000360.jsp.
   Google Scholar
• Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004. Off J Eur Union.  L378: 2006.
   Google Scholar
• Roin BN. Solving the problem of new uses. 2013 Oct 1. [cited 2016 Jun 13]. Available from:  https://ssrn.com/abstract=2337821
   Google Scholar
• American Heart Association. Medications used to treat heart failure. 2016 Sep 28. [cited 2016 Jun 13]. Available from: http://www.heart.org/HEARTORG/Conditions/HeartFailure/TreatmentOptionsForHeartFailure/Medications-Used-to-Treat-Heart-Failure_UCM_306342_Article.jsp#.V162wISyNBc
   Google Scholar
• Collins M. Bayer AG is Pitching for a Big Win in Heart Failure. Market Exclusive. 2016 Feb 17. [cited 2016 Jun 13]. Available from: https://marketexclusive.com/bayer-ag-otcmktsbayry-is-pitching-for-a-big-win-in-heart-failure/3046/.
   Google Scholar
• Murteira S, Millier A, Ghezaiel Z, et al. Drug reformulations and repositioning in the pharmaceutical industry and their impact on market access: regulatory implications. J Market Access Health Policy. 2014;2. DOI: 10.3402/jmahp.v2.22813
   Google Scholar
• Rejón-Parrilla JC, Hernández-Villafuerte K, Shah K, et al. The expanding value footprint of oncology treatments. London: Office of Health Economics; 2014.
   Google Scholar
• Reynolds J, Bruce I. Overview of the management of systemic lupus erythematosus. Rep Rheum Dis. 2013;7(2):1–11.
   Google Scholar
• Medicines Complete. British National Formulary (UK). [ cited 2015 May 15]. Available from: https://www.medicinescomplete.com/mc/bnf/current/.
   Google Scholar
• Datamonitor. Systemic lupus erythematosus. Pipeline: Datamonitor Healthcare; 2014. DMKC0045271.
   Google Scholar
• NICE. Ulcerative colitis: management [CG166]. 2013.
   Google Scholar
• NICE. Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy [TA329]. 2015.
   Google Scholar
• Schlier M. Pourquoi les médecins généralistes prescrivent-ils hors AMM?: etude qualitative évaluant la prescription du Kardégic® hors AMM auprès de médecins généralistes et discussion autour de la discordance antre AMM et recommandations [dissertation]. Strasbourg: Université de Strasbourg; 2013.
   Google Scholar
• Casali PG; Executive Committee of ESMO. The off-label use of drugs in oncology: a position paper by the European Society for Medical Oncology (ESMO). Ann Oncol. 2007;18(12):1923–1925.
   Web of Science ®Google Scholar
• Brosgart CL, Mitchell T, Charlebois E, et al. Off-label drug use in human immunodeficiency virus disease. J Acquir Immune Defic Syndr. 1996;12(1):56–62.
   Web of Science ®Google Scholar
• Lenk C, Duttge G. Ethical and legal framework and regulation for off-label use: european perspective. Ther Clin Risk Manag. 2014;10:537–546.
   Web of Science ®Google Scholar
• Ashburn TT, Thor KB. Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov. 2004;3(8):673–683.
   PubMed Web of Science ®Google Scholar
• Arrowsmith J, Miller P. Trial watch: phase II and phase III attrition rates 2011-2012. Nat Rev Drug Discov. 2013;12(8):569.
   PubMed Web of Science ®Google Scholar
• Toumi M, Jadot G. Economic impact of new active substance status on EU payers’ budgets: example of dimethyl fumarate (Tecfidera®) for multiple sclerosis. J Market Access Health Policy. 2014;2. DOI: 10.3402/jmahp.v2.23932.
   Google Scholar
• Bomprezzi R. Dimethyl fumarate in the treatment of relapsing–remitting multiple sclerosis: an overview. Ther Adv Neurol Disord. 2015;8(1):20–30.
   PubMed Web of Science ®Google Scholar
• eMC. Certican®. Summary of product characteristics. [cited 2015 Nov 17]. Available from: https://www.medicines.org.uk/emc/medicine/30306.
   Google Scholar
• EMA. Afinitor® Summary of Product Characteristics. [ cited2015 Nov 17]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001038/WC500022814.pdf.
   Google Scholar
• EMA. Votubia®. Summary of Product Characteristics. [ cited 2015 Nov 17]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002311/WC500112238.pdf.
   Google Scholar
• Ameli l’Assurance Maladie. Price Database (France). [ cited 2015 Nov 17]. Available from: http://www.codage.ext.cnamts.fr/codif/bdm_it/index.php?p_site=AMELI.
   Google Scholar
• EMA. Hemangiol®. Summary of Product Characteristics. [ cited 2015 Nov 17]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002621/WC500166910.pdf.
   Google Scholar
• Zaide F. Data exclusivity, market protection and paediatric rewards. Workshop for Micro, Small and Medium Sized Enterprises. London: EMA; 2013  Apr 23.
   Google Scholar
• EMA. Orphan incentives. [ cited 2015 Nov 17]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000393.jsp.
   Google Scholar
• EMA. Rewards and incentives for paediatric medicines. [ cited 2015 Nov 17]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000607.jsp&mid=WC0b01ac0580925b1c.
   Google Scholar
• EPO - “Swiss-type” medical claim format no longer allowed. Maucher Jenkins. 2010 Mar 3. [cited 2016 Aug 2]. Available from: http://www.maucherjenkins.com/news-and-publications/articles/EPO-Swiss-type-medical-claim-format-no-longer-allowed.
   Google Scholar
• Kremer S, Jones R. Old drugs, new tricks: patent considerations in drug repurposing.Lexology. 2015 Jan 28. [cited 2016 Aug 2]. Available from: http://www.lexology.com/library/detail.aspx?g=0e11981f-5268-4b0f-b6a6-1cb27e97e07c
   Google Scholar
• Winter G. Pfizer loses Lyrica patent infringement case. Pharm J. 2015;295(7880). DOI: 10.1211/PJ.2015.20069353M
   Google Scholar
• Hirschler B. Pfizer loses UK patent case over use of Lyrica drug in pain. Reuters. 2015 Sep 10. [cited 2016 Aug 2]. Available from: http://www.reuters.com/article/us-pfizer-britain-lyrica-idUSKCN0RA1G120150910.
   Google Scholar